128 related articles for article (PubMed ID: 28977854)
21. The clinicopathological significance of CD44+/CD24-/low and CD24+ tumor cells in invasive micropapillary carcinoma of the breast.
Li W; Liu F; Lei T; Xu X; Liu B; Cui L; Wei J; Guo X; Lang R; Fan Y; Gu F; Tang P; Zhang X; Fu L
Pathol Res Pract; 2010 Dec; 206(12):828-34. PubMed ID: 20977976
[TBL] [Abstract][Full Text] [Related]
22. Uncoupling of the ERα regulated morphological phenotype from the cancer stem cell phenotype in human breast cancer cell lines.
Gadalla SE; Alexandraki A; Lindström MS; Nistér M; Ericsson C
Biochem Biophys Res Commun; 2011 Feb; 405(4):581-7. PubMed ID: 21266162
[TBL] [Abstract][Full Text] [Related]
23. Molecular Pathways Mediating Metastases to the Brain via Epithelial-to-Mesenchymal Transition: Genes, Proteins, and Functional Analysis.
Jeevan DS; Cooper JB; Braun A; Murali R; Jhanwar-Uniyal M
Anticancer Res; 2016 Feb; 36(2):523-32. PubMed ID: 26851006
[TBL] [Abstract][Full Text] [Related]
24. RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.
Palafox M; Ferrer I; Pellegrini P; Vila S; Hernandez-Ortega S; Urruticoechea A; Climent F; Soler MT; Muñoz P; Viñals F; Tometsko M; Branstetter D; Dougall WC; González-Suárez E
Cancer Res; 2012 Jun; 72(11):2879-88. PubMed ID: 22496457
[TBL] [Abstract][Full Text] [Related]
25. Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer.
Ryu HS; Park DJ; Kim HH; Kim WH; Lee HS
Hum Pathol; 2012 Apr; 43(4):520-8. PubMed ID: 22018628
[TBL] [Abstract][Full Text] [Related]
26. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
[TBL] [Abstract][Full Text] [Related]
27. CD24 regulates stemness and the epithelial to mesenchymal transition through modulation of Notch1 mRNA stability by p38MAPK.
Lim J; Lee KM; Shim J; Shin I
Arch Biochem Biophys; 2014 Sep; 558():120-6. PubMed ID: 24977325
[TBL] [Abstract][Full Text] [Related]
28. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion.
Cho SH; Park YS; Kim HJ; Kim CH; Lim SW; Huh JW; Lee JH; Kim HR
Int J Oncol; 2012 Jul; 41(1):211-8. PubMed ID: 22552741
[TBL] [Abstract][Full Text] [Related]
29. CD24 expression and stem-associated features define tumor cell heterogeneity and tumorigenic capacities in a model of carcinogenesis.
Ortiz-Montero P; Liu-Bordes WY; Londoño-Vallejo A; Vernot JP
Cancer Manag Res; 2018; 10():5767-5784. PubMed ID: 30510447
[TBL] [Abstract][Full Text] [Related]
30. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
[TBL] [Abstract][Full Text] [Related]
31. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M
Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632
[TBL] [Abstract][Full Text] [Related]
32. Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells.
Pommier SJ; Quan GG; Christante D; Muller P; Newell AE; Olson SB; Diggs B; Muldoon L; Neuwelt E; Pommier RF
Ann Surg Oncol; 2010 Feb; 17(2):613-23. PubMed ID: 19838757
[TBL] [Abstract][Full Text] [Related]
33. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
[TBL] [Abstract][Full Text] [Related]
34. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
Chen Y; Song J; Jiang Y; Yu C; Ma Z
Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of epithelial-mesenchymal transition-related markers according to cell dedifferentiation: clinical implications as an independent predictor of poor prognosis in cholangiocarcinoma.
Ryu HS; Chung JH; Lee K; Shin E; Jing J; Choe G; Kim H; Xu X; Lee HE; Kim DG; Lee H; Jang JJ
Hum Pathol; 2012 Dec; 43(12):2360-70. PubMed ID: 23084587
[TBL] [Abstract][Full Text] [Related]
36. Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castillo B; Cufí S; Del Barco S; Lopez-Bonet E; Brunet J; Menendez JA
Biochem Biophys Res Commun; 2010 Jun; 397(1):27-33. PubMed ID: 20470755
[TBL] [Abstract][Full Text] [Related]
37. Metadherin enhances the invasiveness of breast cancer cells by inducing epithelial to mesenchymal transition.
Li X; Kong X; Huo Q; Guo H; Yan S; Yuan C; Moran MS; Shao C; Yang Q
Cancer Sci; 2011 Jun; 102(6):1151-7. PubMed ID: 21371176
[TBL] [Abstract][Full Text] [Related]
38. Modulation of tumorigenesis and oestrogen receptor-alpha expression by cell culture conditions in a stem cell-derived breast epithelial cell line.
Wang KH; Kao AP; Chang CC; Lee JN; Chai CY; Hou MF; Liu CM; Tsai EM
Biol Cell; 2010 Jan; 102(3):159-72. PubMed ID: 19895368
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral Morphological Heterogeneity of Breast Cancer As an Indicator of the Metastatic Potential and Tumor Chemosensitivity.
Gerashchenko TS; Zavyalova MV; Denisov EV; Krakhmal NV; Pautova DN; Litviakov NV; Vtorushin SV; Cherdyntseva NV; Perelmuter VM
Acta Naturae; 2017; 9(1):56-67. PubMed ID: 28461975
[TBL] [Abstract][Full Text] [Related]
40. Interrogation of Phenotypic Plasticity between Epithelial and Mesenchymal States in Breast Cancer.
Bhatia S; Monkman J; Blick T; Pinto C; Waltham M; Nagaraj SH; Thompson EW
J Clin Med; 2019 Jun; 8(6):. PubMed ID: 31234417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
